btx-a51
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 6, 2020 (NCT04243785)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Casein kinase I alphaINHIBITOR
CSNK1A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1ncc(-c2nc(N[C@H]3CC[C@H](N)CC3)ncc2Cl)c1CC1CC1- Mol. weight
- 360.89 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4754493 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06414434 | Phase 1 | Sep 30, 2024 | Harvard University |
| NCT04872166 | Phase 1 | Jun 7, 2021 | BioTheryX, Inc. |
| NCT04243785 | Phase 1 | Jan 6, 2020 | BioTheryX, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioTheryX, Inc. | For profit | 2 | 2 | 1 | 2020 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1